250,000 Shares in Evolent Health, Inc. (NYSE:EVH) Bought by Royce & Associates LP

Royce & Associates LP bought a new position in Evolent Health, Inc. (NYSE:EVH - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 250,000 shares of the technology company's stock, valued at approximately $7,070,000. Royce & Associates LP owned approximately 0.21% of Evolent Health at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of EVH. Oppenheimer & Co. Inc. bought a new stake in shares of Evolent Health in the third quarter worth $855,000. Entropy Technologies LP purchased a new position in Evolent Health in the third quarter worth about $319,000. Los Angeles Capital Management LLC bought a new stake in shares of Evolent Health during the 3rd quarter valued at about $430,000. State of New Jersey Common Pension Fund D purchased a new stake in shares of Evolent Health during the 3rd quarter valued at about $1,774,000. Finally, Covestor Ltd increased its position in shares of Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company's stock valued at $40,000 after purchasing an additional 826 shares during the last quarter.

Evolent Health Price Performance

EVH traded down $0.03 during trading on Monday, hitting $12.35. 1,878,532 shares of the company traded hands, compared to its average volume of 1,772,556. The company has a current ratio of 1.04, a quick ratio of 1.08 and a debt-to-equity ratio of 0.58. The company has a market cap of $1.44 billion, a PE ratio of -13.63 and a beta of 1.58. The stock's 50-day simple moving average is $25.11 and its two-hundred day simple moving average is $24.29. Evolent Health, Inc. has a 1 year low of $12.18 and a 1 year high of $35.00.

Insider Activity

In other Evolent Health news, CFO John Paul Johnson sold 44,693 shares of Evolent Health stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $1,340,790.00. Following the completion of the transaction, the chief financial officer now directly owns 171,207 shares of the company's stock, valued at $5,136,210. This trade represents a 20.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Seth Blackley sold 187,904 shares of the company's stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the sale, the chief executive officer now owns 411,924 shares in the company, valued at $12,357,720. This represents a 31.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 307,291 shares of company stock worth $9,290,385 over the last 90 days. Corporate insiders own 1.60% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on EVH. KeyCorp assumed coverage on shares of Evolent Health in a research report on Friday, October 11th. They set an "overweight" rating and a $35.00 target price for the company. Barclays cut their price objective on shares of Evolent Health from $39.00 to $19.00 and set an "overweight" rating for the company in a research report on Monday, November 11th. Stephens cut Evolent Health from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $38.00 to $16.00 in a report on Friday, November 8th. Royal Bank of Canada reissued an "outperform" rating and set a $20.00 price target on shares of Evolent Health in a report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. raised their price objective on Evolent Health from $36.00 to $45.00 and gave the stock an "overweight" rating in a research note on Monday, August 19th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Evolent Health presently has a consensus rating of "Buy" and a consensus price target of $28.90.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.